The Problem with Waiting for Symptoms
Heart disease in dogs follows a predictable and unfortunate pattern: months to years of silent progression, then sudden clinical decompensation. By the time an owner notices coughing, exercise intolerance, or labored breathing, the disease is often advanced. Congestive heart failure is the endpoint of a process that started much earlier.
Cardiac biomarkers change that timeline. Two blood tests — cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) — can detect cardiac damage and cardiac stress before symptoms appear, before auscultation finds a murmur in some cases, and well before radiographic changes develop.
Oyama et al. (2008) demonstrated that NT-proBNP reliably distinguishes dogs with cardiac disease from those with respiratory disease presenting with similar clinical signs. More importantly for screening purposes, biomarkers can flag preclinical disease — the window where intervention is most effective.
What Each Biomarker Measures
Cardiac troponin I (cTnI) is a structural protein found only in cardiac muscle cells (cardiomyocytes). When cardiomyocytes are damaged or die, cTnI leaks into the bloodstream. Elevated cTnI means active myocardial injury is occurring. It is the cardiac equivalent of what ALT is for the liver — a direct marker of cellular damage.
Ljungvall et al. (2010) showed that cTnI levels correlate with severity of mitral valve disease in dogs, increase with age, and track with inflammatory markers. cTnI is also elevated in myocarditis, cardiac contusion, severe arrhythmias, and pericardial disease.
NT-proBNP is a hormone fragment released by ventricular cardiomyocytes when they are stretched by volume or pressure overload. Elevated NT-proBNP means the heart is working harder than normal — the chambers are dilated, the walls are under stress, or both. It does not indicate cell death (that is cTnI’s domain), but rather hemodynamic burden.
Together, the two markers answer distinct questions:
- cTnI: “Are heart muscle cells being damaged?”
- NT-proBNP: “Is the heart under hemodynamic stress?”
A dog can have elevated NT-proBNP with normal cTnI (compensated volume overload without active damage), elevated cTnI with normal NT-proBNP (acute myocardial injury without chronic remodeling), or both elevated (active damage plus hemodynamic stress — the most concerning pattern).
Breed-Specific Screening Protocols
Cardiac disease predisposition varies dramatically by breed. Biomarker screening provides the highest return on investment in high-risk breeds:
Cavalier King Charles Spaniels. Nearly 100% develop myxomatous mitral valve disease by age 10. Annual NT-proBNP starting at age 3-4 detects early valvular degeneration before murmur onset. See cardiovascular screening for small breeds for the full protocol.
Doberman Pinschers. Dilated cardiomyopathy prevalence reaches 45-58% in some populations (Wess et al., 2010). Annual cTnI and NT-proBNP starting at age 3-4, combined with Holter monitoring and echocardiography, forms the standard screening protocol. DCM in Dobermans can progress from preclinical to sudden death with little warning.
Boxer. Arrhythmogenic right ventricular cardiomyopathy (ARVC) causes arrhythmias that may not produce volume overload detectable by NT-proBNP alone. cTnI plus Holter monitoring is the preferred screening combination.
Great Dane, Irish Wolfhound. Giant breed DCM predisposition. Baseline biomarkers by age 3, then annual screening.
Large breeds generally. Annual NT-proBNP starting at age 6-7 as part of comprehensive wellness screening catches occult cardiac disease earlier than auscultation alone.
Interpreting Results
NT-proBNP reference ranges (lab-specific, but generally):
- <900 pmol/L: Cardiac disease unlikely
- 900-1800 pmol/L: Equivocal — echocardiography recommended
-
1800 pmol/L: Cardiac disease probable — echocardiography and treatment planning indicated
cTnI reference ranges:
- <0.10 ng/mL: Normal
- 0.10-0.50 ng/mL: Mild elevation — possible subclinical myocardial injury. Recheck and trend.
-
0.50 ng/mL: Significant myocardial injury. Full cardiac workup indicated.
Important caveats: reference ranges vary by laboratory and assay platform. Non-cardiac conditions including severe systemic illness, kidney disease, and sepsis can elevate both markers. Always interpret in clinical context.
The EPIC Trial and Why Early Detection Matters
The EPIC trial (Boswood et al., 2016) transformed the treatment of preclinical mitral valve disease in dogs. The study demonstrated that pimobendan started in dogs with preclinical MVD (ACVIM Stage B2) delayed the onset of congestive heart failure by a median of 15 months.
The key: dogs had to be identified in the preclinical phase for this benefit to apply. Cardiac biomarkers, combined with echocardiography, are the tools that identify Stage B2 disease before symptoms develop. Without biomarker screening, many of these dogs would have been diagnosed only after progressing to heart failure.
This is the concrete clinical case for cardiac biomarker screening: earlier detection enables earlier intervention, and earlier intervention extends the symptom-free interval by over a year.
Practical Application: Integration with Annual Screening
For dogs at average cardiac risk, the most practical integration is adding NT-proBNP to annual wellness bloodwork starting at age 6-7 for large breeds or 8-9 for small breeds. See annual wellness testing protocol for the broader framework.
For high-risk breeds (Cavaliers, Dobermans, Boxers, giant breeds), both cTnI and NT-proBNP should be part of breed-specific screening starting at age 3-4, combined with annual echocardiography.
Cost for NT-proBNP is typically $60-120 per test. cTnI adds another $50-80. For high-risk breeds, this is among the highest-value screening investments available. See canine cardiac monitoring protocol for detailed monitoring schedules.
Common Mistakes
- Relying on auscultation alone for cardiac screening. Murmurs can be absent in early DCM and in some cases of MVD. Biomarkers detect disease that physical examination misses.
- Interpreting a single normal biomarker result as clearance in a high-risk breed. Cardiac disease is progressive. Annual screening is required because last year’s normal result does not predict this year’s status.
- Using NT-proBNP to distinguish cardiac from respiratory disease without recognizing that both conditions can coexist, particularly in older dogs.
- Ordering cardiac biomarkers without a plan for what to do with abnormal results. Echocardiography is the definitive follow-up, and it should be available before screening is initiated.
- Ignoring mild cTnI elevations. Even borderline elevations indicate cardiomyocyte injury and warrant trending at minimum.
Frequently Asked Questions
What is the difference between troponin and proBNP in dogs?
Troponin I measures active cardiac muscle cell damage — it leaks from injured cells. NT-proBNP measures cardiac hemodynamic stress — it is released when heart chambers are stretched by pressure or volume overload. Together they detect both injury and functional burden.
How much does cardiac biomarker testing cost?
NT-proBNP typically costs $60-120 per test, and cardiac troponin I adds $50-80. For breeds predisposed to heart disease, this screening cost is far less than the cost of managing advanced heart failure.
Can cardiac biomarkers detect heart disease before a murmur is audible?
Yes. NT-proBNP can be elevated before a murmur develops in myxomatous mitral valve disease, and both biomarkers can detect occult dilated cardiomyopathy in Dobermans before any auscultatory abnormality is present.
My dog’s NT-proBNP came back in the equivocal range. What now?
An equivocal result (typically 900-1800 pmol/L) warrants echocardiography to directly visualize cardiac structure and function. The biomarker flags the possibility; the echocardiogram confirms or rules out the diagnosis.
Should all dogs get cardiac biomarker screening?
Not necessarily all breeds at all ages. The highest value is in breeds predisposed to heart disease and in senior dogs as part of comprehensive wellness screening. For average-risk breeds, adding NT-proBNP to annual bloodwork after age 6-7 (large breeds) or 8-9 (small breeds) is a reasonable, cost-effective approach.
Bottom Line
Cardiac troponin I and NT-proBNP detect heart disease in dogs before symptoms appear, enabling earlier intervention that meaningfully extends survival. For breeds predisposed to DCM and MVD, annual biomarker screening starting at age 3-4 is the standard of care. For all dogs, adding NT-proBNP to senior wellness panels catches occult cardiac disease during the window when treatment makes the most difference.